sur MIRA Pharmaceuticals (NASDAQ:MIRA)
MIRA Pharmaceuticals' Ketamir-2 Manuscript Accepted for Publication
MIRA Pharmaceuticals announced that its lead drug candidate, Ketamir-2, has been accepted for publication in the journal Frontiers in Pharmacology. Ketamir-2, currently in a Phase 1 trial for neuropathic pain, is highlighted for its pharmacological differentiation from ketamine.
The article details Ketamir-2 as a low-affinity NMDA receptor antagonist with a clean pharmacological profile. Unlike ketamine, it does not interact significantly with other systems such as dopamine or serotonin.
In preclinical models, Ketamir-2 did not induce hyperlocomotion, suggesting a favorable safety profile. It also demonstrated antidepressant and anxiolytic effects in behavioral tests.
The drug proves effective in oral administration, efficiently crossing the blood-brain barrier. MIRA plans to initiate a Phase 2a trial by the end of 2025.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MIRA Pharmaceuticals